Consensus Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Market Closed - Nyse Other stock markets 01:30:02 04/05/2024 am IST			5-day change	1st Jan Change
13.6 ^USD	-1.88%		-8.05%	-20.28%

02/05	RBC Capital Reviews Bausch + Lomb's Q1 Results	MT
02/05	Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	MT

Evolution of the average Target Price on Bausch + Lomb Corporation

Price target over the last 5 years

History of analyst recommendation changes

c0bf316f882d2d.rQyjx_RRbO7-GwO5pGUgolMEa28L8vhOp1jCWaaYP8M.9Ub7icwWG9m_VDD17TBW82ZXGghSvtV88BGvH9DpCY-dOefq2QIrg4hXdA~ee6a4ef69886eb2a758f9b07eddc55ce

Analyst Recommendations on Bausch + Lomb Corporation

Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	02/05	MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating	22/04	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	05/04	MT
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	26/02	MT
Wells Fargo Ups Price Target on Bausch + Lomb to $23 From $21, Maintains Overweight Rating	22/02	MT
RBC Lifts Price Target on Bausch + Lomb to $20 From $19 After Better-Than-Expected Q4, Above-Consensus 2024 Revenue Guidance; Outperform Kept	22/02	MT
RBC Trims Price Target on Bausch + Lomb to $19 From $20 Ahead of Q4 2023 Report, Keeps Outperform Rating	09/02	MT
Evercore ISI Downgrades Bausch + Lomb to In Line From Outperform, Adjusts Price Target to $17 From $19	04/01	MT
Stifel Initiates Bausch + Lomb With Hold Rating, $16 Price Target	12/12	MT
Morgan Stanley Trims Price Target on Bausch + Lomb to $16 From $17, Maintains Equal-Weight Rating	04/12	MT
RBC Trims Price Target on Bausch + Lomb to $20 From $21 Amid Foreign-Exchange Headwinds, Keeps Outperform Rating	23/23/23	MT
Morgan Stanley Adjusts Price Target on Bausch + Lomb to $18.50 From $20, Keeps Equalweight Rating	13/23/13	MT
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained	04/23/04	MT
Moody's Rates Bausch + Lomb's New Secured Debt Instruments	12/23/12	MT
Fitch Assigns Rating to Bausch + Lomb's Secured Term Loan, Secured Bond; Up 1.4%	11/23/11	MT
Barclays Adjusts Price Target on Bausch + Lomb to $19 From $18, Maintains Equalweight Rating	03/23/03	MT
Needham & Co Maintains Hold Rating on Bausch + Lomb After Q2	03/23/03	MT
Toronto Stocks Drop Amid U.S. Credit-Rating Downgrade; Cameco Shares Down	02/23/02	DJ
TSX futures decline after Fitch downgrades US credit rating	02/23/02	RE
RBC Lifts Price Target on Bausch + Lomb to $21 From $20 Ahead of Q2 Report, Maintains Outperform Rating	24/23/24	MT
BofA Securities Raises Price Target on Bausch + Lomb to $23 From $19, Maintains Buy Rating	03/23/03	MT
Needham & Co "Incrementally More Positive" on Bausch + Lomb After Xiidra Announcement, But Maintains Hold Rating	30/23/30	MT
HC Wainwright Adjusts Price Target on Bausch + Lomb to $22 From $19, Keeps Buy Rating	19/23/19	MT
Barclays Adjusts Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	05/23/05	MT
RBC Cuts Price Target on Bausch Health to $8 From $9, Notes Concerns for Ability to Distribute Bausch + Lomb Shares, Keeps Sector Perform Rating	05/23/05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.6 USD

Average target price

18.57 USD

Spread / Average Target

+36.55%

High Price Target

25 USD

Spread / Highest target

+83.82%

Low Price Target

14 USD

Spread / Lowest Target

+2.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bausch + Lomb Corporation

Deutsche Bank Securities
RBC Capital Markets
Barclays
Wells Fargo Securities
Evercore ISI
Stifel Nicolaus
Morgan Stanley
BofA Securities
HC Wainwright
Needham & Co.
Goldman Sachs
Citigroup
Jefferies & Co.
Guggenheim
JPMorgan Chase
Cowen

Ratings for Bausch + Lomb Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar